In some cases, an applicant may seek to augment the information provided in the original NDA during the review
process. For example, the applicant may submit a new analysis of previously submitted data or information needed to
address a deficiency in the drug application.
Any such information provided for an unapproved application is considered an NDA amendment. The submission of a
significant amendment may result in an extension of FDA's time line for application review.